Ex vivo fucosylation of third-party human regulatory T cells enhances anti-graft-versus-host disease potency in vivo.
about
Inducing and Administering Tregs to Treat Human DiseaseThe Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host DiseaseAdoptive immunotherapy with the use of regulatory T cells and virus-specific T cells derived from cord bloodUnbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD.Immunological basis for treatment of graft versus host disease after liver transplant.Strategies to accelerate immune recovery after allogeneic hematopoietic stem cell transplantation.T-lymphocyte homing: an underappreciated yet critical hurdle for successful cancer immunotherapy.Mechanistic approaches for the prevention and treatment of chronic GVHD.Glycoengineering of E-Selectin Ligands by Intracellular versus Extracellular Fucosylation Differentially Affects Osteotropism of Human Mesenchymal Stem Cells.New and emerging therapies for acute and chronic graft versus host disease.Optimizing human Treg immunotherapy by Treg subset selection and E-selectin ligand expression.Engineered Glycocalyx Regulates Stem Cell Proliferation in Murine Crypt Organoids.miR-466a Targeting of TGF-β2 Contributes to FoxP3+ Regulatory T Cell Differentiation in a Murine Model of Allogeneic Transplantation.Clinical Grade Regulatory CD4+ T Cells (Tregs): Moving Toward Cellular-Based Immunomodulatory Therapies.generation of umbilical cord blood T regulatory cells expressing the homing markers CD62L and cutaneous lymphocyte antigenImproving Immunotherapy Through Glycodesign
P2860
Q26772723-5992321D-AEA3-40FF-836A-5ADCB39EFABBQ28076264-0576D6B2-681C-4AEE-ACBF-E73E419F05D3Q35582326-806C191E-FBF6-4AD7-9B29-6772A01447BFQ36547819-E5141850-C9DD-4E08-80A0-6E8E7AA67C65Q37114440-A6FCB9B9-522E-4B07-9B08-44AD531C36D2Q38640239-FF9CB285-42AF-4060-873A-884D3BE60FE3Q38873974-237DCD73-FED7-4078-8E9A-A444CD16C1E5Q39002166-B8BA5C05-0706-46D0-95E3-E90AD1DE2B54Q41657642-FCC7A40D-D2E1-4C4E-958D-B23C0E257BC4Q49238507-68F9002F-9858-4E30-A6D8-76C131AB9326Q49702312-87C6CD36-66F9-4BCB-B2F3-339177D8E80CQ50074949-FC6CD8A6-B53C-4F49-9047-A378EF5B6A27Q52568333-4F990AC8-9E78-433A-B584-CDEBAEAB3CF4Q52682313-5F289EC7-F709-41CF-ABCF-75B2FE6DE57EQ58739873-AE103D51-38FB-4E65-823E-176DEBE31B0AQ59132146-4A690A7B-0DFC-430B-A55E-6C063D241E59
P2860
Ex vivo fucosylation of third-party human regulatory T cells enhances anti-graft-versus-host disease potency in vivo.
description
2014 nî lūn-bûn
@nan
2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Ex vivo fucosylation of third- ...... -host disease potency in vivo.
@ast
Ex vivo fucosylation of third- ...... -host disease potency in vivo.
@en
type
label
Ex vivo fucosylation of third- ...... -host disease potency in vivo.
@ast
Ex vivo fucosylation of third- ...... -host disease potency in vivo.
@en
prefLabel
Ex vivo fucosylation of third- ...... -host disease potency in vivo.
@ast
Ex vivo fucosylation of third- ...... -host disease potency in vivo.
@en
P2093
P2860
P1433
P1476
Ex vivo fucosylation of third- ...... -host disease potency in vivo.
@en
P2093
Amer Najjar
Bruce R Blazar
Elizabeth J Shpall
Ian McNiece
Katy Rezvani
Leonard Miller
Patrick Zweidler-McKay
P2860
P304
P356
10.1182/BLOOD-2014-10-603449
P407
P577
2014-11-26T00:00:00Z